Total Payments
$17,301
2023 Payments
$78.26
Companies
19
Transactions
60
Payment Breakdown by Category
Consulting$14,560 (84.2%)
Food & Beverage$2,418 (14.0%)
Travel$218.64 (1.3%)
Education$104.13 (0.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $14,560 | 10 | 84.2% |
| Food and Beverage | $2,418 | 41 | 14.0% |
| Travel and Lodging | $218.64 | 6 | 1.3% |
| Education | $104.13 | 3 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $8,105 | 13 | $0 (2019) |
| Celgene Corporation | $2,996 | 7 | $0 (2019) |
| Janssen Biotech, Inc. | $2,579 | 9 | $0 (2019) |
| Puma Biotechnology, Inc. | $1,169 | 4 | $0 (2019) |
| COMSORT, Inc | $450.00 | 3 | $0 (2018) |
| BAXTER HEALTHCARE | $350.00 | 1 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $312.82 | 3 | $0 (2019) |
| Alexion Pharmaceuticals, Inc. | $249.96 | 2 | $0 (2018) |
| Genentech USA, Inc. | $214.50 | 2 | $0 (2019) |
| Clovis Oncology, Inc. | $125.60 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $78.26 | 1 | TG Therapeutics, Inc. ($78.26) |
| 2022 | $14.99 | 1 | ABBVIE INC. ($14.99) |
| 2021 | $40.45 | 2 | Pharmacyclics LLC, An AbbVie Company ($22.92) |
| 2019 | $10,117 | 23 | Celgene Corporation ($2,908) |
| 2018 | $1,492 | 19 | AstraZeneca Pharmaceuticals LP ($425.95) |
| 2017 | $5,558 | 14 | AstraZeneca Pharmaceuticals LP ($4,816) |
All Payment Transactions
60 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/08/2023 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $78.26 | General |
| Category: Immunology | ||||||
| 01/20/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: NEUROSCIENCE | ||||||
| 12/22/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $17.53 | General |
| Category: NEUROSCIENCE | ||||||
| 10/14/2021 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $22.92 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2019 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Travel and Lodging | Cash or cash equivalent | $57.72 | General |
| Category: Oncology | ||||||
| 11/05/2019 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $2,340.00 | General |
| Category: Oncology | ||||||
| 10/26/2019 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Oncology | ||||||
| 10/26/2019 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: Oncology | ||||||
| 10/26/2019 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: Oncology | ||||||
| 08/12/2019 | Celgene Corporation | Revlimid (Drug) | Travel and Lodging | Cash or cash equivalent | $48.72 | General |
| Category: Hematology / Oncology | ||||||
| 08/12/2019 | Celgene Corporation | Revlimid (Drug) | Travel and Lodging | Cash or cash equivalent | $18.00 | General |
| Category: Hematology / Oncology | ||||||
| 07/29/2019 | BAXTER HEALTHCARE | BioPharma Sol - Research Devel (Biological) | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| Category: BioPharma Solutions | ||||||
| 07/23/2019 | Celgene Corporation | Revlimid (Drug) | Consulting Fee | Cash or cash equivalent | $2,695.00 | General |
| Category: Hematology / Oncology | ||||||
| 07/19/2019 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $120.58 | General |
| Category: Hematology / Oncology | ||||||
| 07/19/2019 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $26.00 | General |
| Category: Hematology / Oncology | ||||||
| 05/18/2019 | Puma Biotechnology, Inc. | Nerlynx (Drug) | Travel and Lodging | Cash or cash equivalent | $46.40 | General |
| Category: Oncology | ||||||
| 05/18/2019 | Puma Biotechnology, Inc. | Nerlynx (Drug) | Travel and Lodging | Cash or cash equivalent | $5.00 | General |
| Category: Oncology | ||||||
| 05/09/2019 | Puma Biotechnology, Inc. | Nerlynx (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Oncology | ||||||
| 05/09/2019 | Puma Biotechnology, Inc. | Nerlynx (Drug) | Food and Beverage | In-kind items and services | $117.11 | General |
| Category: Oncology | ||||||
| 04/30/2019 | Genentech USA, Inc. | Herceptin (Biological), TECENTRIQ | Food and Beverage | In-kind items and services | $94.75 | General |
| Category: BioOncology | ||||||
| 04/25/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $68.99 | General |
| Category: Oncology | ||||||
| 04/18/2019 | Advanced Accelerator Applications | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $105.86 | General |
| Category: Radioactive targeted therapy - Neuroendocrine tumors | ||||||
| 04/10/2019 | Janssen Biotech, Inc. | Erleada (Drug), DARZALEX | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: Oncology | ||||||
| 03/21/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $72.94 | General |
| Category: ONCOLOGY | ||||||
| 03/05/2019 | Janssen Biotech, Inc. | Erleada (Drug), DARZALEX | Food and Beverage | In-kind items and services | $24.91 | General |
| Category: Oncology | ||||||
About Dr. Michael Harris, MD
Dr. Michael Harris, MD is a Hematology & Oncology healthcare provider based in Puyallup, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/29/2007. The National Provider Identifier (NPI) number assigned to this provider is 1932245644.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Harris, MD has received a total of $17,301 in payments from pharmaceutical and medical device companies, with $78.26 received in 2023. These payments were reported across 60 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($14,560).
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Puyallup, WA
- Active Since 01/29/2007
- Last Updated 10/08/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1932245644
Products in Payments
- IMFINZI (Drug) $4,829
- Revlimid (Drug) $2,958
- CALQUENCE (Drug) $2,794
- IMBRUVICA (Drug) $2,536
- Nerlynx (Drug) $1,169
- KEYTRUDA (Biological) $762.82
- TAGRISSO (Drug) $481.88
- BioPharma Sol - Research Devel (Biological) $350.00
- SOLIRIS (Drug) $249.96
- Rubraca (Drug) $125.60
- ZEJULA (Drug) $125.00
- Halaven (Drug) $122.53
- Rituxan (Biological) $119.75
- XGEVA (Biological) $109.16
- LUTATHERA (Drug) $105.86
- Herceptin (Biological) $94.75
- ZYTIGA (Drug) $84.95
- BRIUMVI (Drug) $78.26
- Erleada (Drug) $66.11
- OPDIVO (Biological) $57.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.